AWAK bags $20M in Series B financing
Regardless of a difficult market condition, Singapore-based medtech AWAK Technologies has actually raised more than $20 million in a Series B financing round– among the most significant financing raises in Southeast Asia this year. The round was co-led by Lion X Ventures and Vickers Endeavor Partners.
AWAK is establishing a portable peritoneal dialysis gadget that enables users to go through dialysis anywhere, foregoing long hours of fixed treatment and being linked to large-sized makers in medical facilities and centers.
Based upon a news release, the profits from the financing round will go to finishing AWAK’s continuous human medical trial with Singapore General Healthcare Facility, which is being performed ahead of its last essential trial in the United States in 2025.
The fund will likewise be utilized for establishing complementary items that promote house dialysis and incorporate digital options for enhancing home-based care of persistent kidney illness clients.
Online drug store MedEasy nets $750k seed financing
MedEasy, an online drug store in Bangladesh, has actually scored $750,000 in a seed financing round took part by Seedstars International Ventures, Doha Tech Angels, Start-up Bangladesh Limited, Accelerating Asia, and nVentures, to name a few financiers.
The funds will be utilized to improve its operation, boost its platform functions, reach more users, and advance R&D, a press declaration stated.
Given that it introduced 2 years back, the start-up has now over 150,000 users. Aside from growing its client base, MedEasy likewise prepares to introduce a subscription-based function, a digital health tracking system, and an appointment-booking market.
Switzerland OKs DeepBio’s AI prostate cancer medical diagnosis assistance software application
Medical AI start-up DeepBio from South Korea has actually acquired regulative approval from Switzerland for its AI-powered diagnostic assistance software application for prostate cancer.
The Swiss Firm for Restorative Products has actually cleared DeepDx Prostate for commercialisation in Switzerland, according to a news release.
The AI item, which has actually likewise been authorized in Europe, analyses entire slide pictures of prostate needle biopsy tissues utilizing AI to find and localise locations of interest and categorize them by intensity.
Samsung SDS-spinoff Wellysis’s ECG spot gets United States FDA approval
Wellysis, a Samsung SDS spinoff business based in Seoul, has actually gotten the approval of the United States Fda for its wearable ECG spot.
The S-Patch Ex includes a bio-processor for catching precise ECG waveforms. The light-weight gadget can be incorporated with smart phones, tablets, and watches, and is likewise suitable with any commercially offered electrodes and batteries.
The United States FDA approval comes 2 years after the gadget has actually been given a CE mark in Europe. S-Patch Ex is presently being offered in 14 nations worldwide, consisting of the UK, Australia, Thailand and India.